-
Express | US$900 million to help develop CRISPR gene editing therapy, Vertex renews cooperation
Time of Update: 2021-05-10
CTX001 is a gene editing therapy based on CRISPR/Cas9 technology and is being developed to treat sickle cell anemia (SCD) and transfusion-dependent β-thalassemia syndrome (TDT).
CTX001 is an autologous in vitro CRISPR/Cas9 gene editing therapy under development, currently in clinical trials for the treatment of severe patients with TDT or SCD.
-
$900 million to help develop CRISPR gene editing therapy Vertex renews cooperation
Time of Update: 2021-05-09
CTX001 is a gene editing therapy based on CRISPR/Cas9 technology and is being developed to treat sickle cell anemia (SCD) and transfusion-dependent β-thalassemia syndrome (TDT).
CTX001 is an autologous in vitro CRISPR/Cas9 gene editing therapy under development, currently in clinical trials for the treatment of severe patients with TDT or SCD.
-
$900 million to help develop CRISPR gene editing therapy Vertex renews cooperation
Time of Update: 2021-05-02
CTX001 is a gene editing therapy based on CRISPR/Cas9 technology and is being developed to treat sickle cell anemia (SCD) and transfusion-dependent β-thalassemia syndrome (TDT).
CTX001 is an autologous in vitro CRISPR/Cas9 gene editing therapy under development, currently in clinical trials for the treatment of severe patients with TDT or SCD.
-
Sudden security issues! Vertex developed VX-864 to replace the small molecule correction drug VX-814
Time of Update: 2020-11-07
VX-814 Clinical Phase 2 is a randomized, double-blind, placebo-controlled study designed to assess the safety of VX-814 and pharmacogenetics (PK), as well as the ability of AATD patients to improve their α-1 anti-trypsin (AAT) functional levels within 28 days of receiving VX-814 treatment.
-
Sudden security issues! Vertex developed VX-864 to replace the small molecule correction drug VX-814
Time of Update: 2020-11-02
VX-814 Clinical Phase 2 is a randomized, double-blind, placebo-controlled study designed to assess the safety of VX-814 and pharmacogenetics (PK), as well as the ability to improve the level of α-1 anti-tryproteinase (AAT) function in AATD patients within 28 days of receiving VX-814 treatment.
-
Merck spent $230 million to develop cancer therapy with vertex
Time of Update: 2017-01-16
Source: Biovalley 2017-1-16 pharmaceutical giant Merck recently announced that the company has reached a cooperation agreement with biopharmaceuticals, a biopharmaceutical company, and the two sides w